Alternative splicing is a vast source of biological regulation and diversity that is misregulated in cancer and other diseases. To investigate global control of alternative splicing in human cells, we analyzed splicing of mRNAs encoding Bcl2 family apoptosis factors in a genome-wide siRNA screen. The screen identified many regulators of Bcl-x and Mcl1 splicing, notably an extensive network of cell-cycle factors linked to aurora kinase A. Drugs or siRNAs that induce mitotic arrest promote proapoptotic splicing of Bcl-x, Mcl1, and caspase-9 and alter splicing of other apoptotic transcripts. This response precedes mitotic arrest, indicating coordinated upregulation of prodeath splice variants that promotes apoptosis in arrested cells. These shifts correspond to posttranslational turnover of splicing regulator ASF/SF2, which directly binds and regulates these target mRNAs and globally regulates apoptosis. Broadly, our results reveal an alternative splicing network linking cell-cycle control to apoptosis.
INTRODUCTION
Nearly all human precursor messenger RNAs (pre-mRNAs) undergo alternative splicing (AS), with tremendous variation and specificity across tissues, development, and disease (Pan et al., 2008) . This vast complexity is a formidable challenge to experimental and informatic analysis of AS and its physiological roles (Blencowe, 2006) . One emergent concept is that functionally coherent transcript populations, termed RNA ''regulons,'' are coregulated by dedicated RNA-binding proteins (RBPs) to promote specific biological functions (Keene, 2007) . These RBPs, notably SR proteins and hnRNPs, ''decode'' transcript cis elements and control stepwise assembly of spliceosomal snRNPs: U1 at the 5 0 splice -site (ss), then U2 near the 3 0 ss, and finally U5/4/6 (Wahl et al., 2009; Black, 2003) . Splicing control is integrated with signal transduction pathways, promoting dynamic, context-driven regulation. Collectively, these features produce robust cell-and tissue-specific signatures of exon use that shape many aspects of cell fate (Moore and Silver, 2008) . Exon signatures are radically transformed in tumors, but the causes and consequences are unknown.
In this study, we examine AS of Bcl2 family apoptosis regulators Bcl-x and Mcl1. Bcl2-like proteins contain up to four Bcl2-homology (BH) domains (BH1-4) (Hardwick and Youle, 2009 ). Factors possessing all four BH domains, including Bcl2, Bcl-xL, and Mcl1L, antagonize apoptosis by preventing mitochondrial outer membrane permeablization (MOMP), thus sequestering proapoptotic factors in mitochondria. Factors lacking one or more BH domain, including Bid, BAD, and BAX, are proapoptotic and promote MOMP. A finely tuned balance of pro-and antiapoptotic Bcl2-like factors therefore controls mitochondrial integrity and hence downstream steps in apoptosis such as apoptosome formation and caspase activation (Wang and Youle, 2009) . Remarkably, Mcl1 , and some other Bcl2 family mRNAs are alternatively spliced to yield both long (L) antiapoptotic and short (S) proapoptotic forms. For Bcl-x, use of an alternative 5 0 ss in exon 2 excludes the BH1 and BH2 domains (Akgul et al., 2004) . For Mcl1, exon 2 skipping excludes the BH1 and BH2 domains and eliminates the downstream transmembrane domain via frame shift.
Many cis-regulatory elements and trans-acting factors exert combinatorial control of Bcl-x splicing. Most known regulators, including Sam68, ASF/SF2, hnRNP F/H, SRp30c, and RBM25, altered Bcl-x AS in vitro or when overexpressed in cell culture (Cloutier et al., 2008; Zhou et al., 2008; Paronetto et al., 2007; Garneau et al., 2005) . In addition, in RNA interference (RNAi)-based loss-of-function assays, depletion of Sam68 and hnRNPA1 favored Bcl-xL formation, while depletion of U2 snRNP component SF3B1/SAP155 favored Bcl-xS (Paronetto et al., 2007; . Comparably little is known of Mcl1 splicing regulation.
Beyond Bcl2-like factors, caspases, ''death receptors,'' ligands and various adaptors are regulated by AS, suggesting broad roles in controlling apoptosis (Schwerk and SchulzeOsthoff, 2005) . Many apoptosis regulators, including Bcl2-like proteins, are proto-oncogenes that contribute to apoptosis resistance in cancer (Letai, 2008; Fesik, 2005) . Modulation of apoptotic factors by targeting the splicing machinery is thus an attractive strategy to facilitate tumor cell death. Furthermore, while the divergent functions of Bcl-x and Mcl1 isoforms in apoptosis are well established, the physiological contexts and upstream regulation of their expression are poorly defined.
These unanswered questions illustrate a pervasive challenge in defining physiological contexts of AS regulation, because strategies for systematic evaluation of upstream regulation are limited.
Genome-scale screening of RNA regulatory events is complicated by the difficulty of visualizing RNAs in vivo, and the technical infeasibility of high-throughput measurements by RT-PCR and other methods. Splicing-sensitive fluorescent reporters are an alternative strategy that produce a robust, visual output suitable for screening efforts (Stoilov et al., 2008; Warzecha, et al., 2009; Orengo et al., 2006) . Here, we present high-throughput assays that recapitulate physiological regulation of Bcl-x and Mcl1 AS. In a whole-genome siRNA screen, we identified new factors that regulate the balance of anti-and proapoptotic splice isoforms, with striking enrichment for cell-cycle factors. These results define functional interactions between the cell cycle and splicing machineries in human cells that manifest in a coordinated program of AS controlling apoptosis.
RESULTS
Reporter Assays for Bcl-x and Mcl1 Alternative Splicing To develop splicing assays for high-throughput analysis, we designed splicing-sensitive reporters for the Bcl2 family apoptosis regulators Bcl-x and Mcl1. 5 0 untranslated region (UTR), open reading frame (ORF), and intervening intron sequences for Bcl-x and Mcl1 were cloned in C-terminal fusions with Venus (yellow) and mCherry (red) complementary DNAs (cDNAs), respectively ( Figure 1A) . In HeLa cells, these constructs expressed long and short spliced mRNAs at ratios similar to endogenous mRNAs ( Figure 1B ). To render constructs splicing-sensitive, premature termination codons (PTCs) were introduced in alternative exon regions exclusive to long splice forms. As expected, PTCs eliminated expression of long protein variants, but short forms were retained ( Figure 1C ).
To produce screen assay cell lines, splicing reporters were stably transfected into HeLa cells along with a constitutive mCerulean fluorescent protein (CFP) construct. All constructs used the human EF1a promoter, which contains a 5 0 UTR intron, allowing dual measurements of minigene splicing and a constitutively spliced CFP reporter under identical control. To test the Bcl-x reporter line, we verified that siRNA-depletion of known regulator SF3B1 increased Bcl-xS-Venus expression relative to a non-targeting control ( Figure 1D , left panels) . Immunoblotting confirmed efficient siRNA knockdown of SF3B1, and upregulation of Bcl-xS-Venus reporter protein ( Figure 1E ). RT-PCR confirmed upregulation of the Bcl-xSVenus mRNA ( Figure 1F ). Finally, RT-PCR analysis of endogenous Bcl-x transcript in HeLa cells verified that SF3B1 knockdown shifted splicing toward Bcl-xS, demonstrating congruous regulation of minigene and endogenous splicing ( Figure 1G , upper panel).
We had no a priori knowledge of Mcl1 regulators, but SF3B1 knockdown also upregulated Mcl1S-mCherry in the splicing assay, establishing a positive assay control ( Figure 1D , right panels). Analysis of endogenous Mcl1 verified this shift toward Mcl1S ( Figure 1G , lower panel).
High-Throughput siRNA Screens for Alternative Splicing Regulators
To identify regulators of Bcl-x AS, >21,000 siRNA pools targeting known and predicted human genes were screened for upregulation of the Bcl-x reporter (Figure 2A ). Three hundred and sixtynine positive hits were identified with a Support Vector Machine (SVM) model that determined reproducibility (i.e., ''confidence'') across triplicates and signal ''strength'' relative to positive and negative control siRNAs ( Figure 2B , and Figure S1 and Table S1 available online). Hits had strong gene ontology (GO) enrichments for mRNA splicing/processing, protein kinase signaling, cytoskeleton association, and cell-cycle functions ( Figure 2C) . Importantly, the screen blindly recovered positive control SF3B1 and several of its interactors.
For validation, hits were retested in the screen assay with four individual siRNAs from deconvoluted SMARTpools. Two hundred and seventy-four of 369 factors validated with at least one siRNA, and 160 validated with two or more ( Figure 2A and Table S2 ). In the primary and validation screens, Bcl-x-Venus expression correlated significantly with cell death (Figures S2A and S2C) . Venus showed no systematic correlation to CFP, indicating that nonspecific promoter effects were not a major source of positives (Figures S2B and S2F) . In the validation screen, apoptosis was tracked by Annexin-V-Cy5 staining and showed strong coupling to proapoptotic Bcl-x splicing and cell death ( Figures S2D and S2E ). Functional enrichments, notably splicing and cell-cycle regulation, were similar between validated hits and the primary screen ( Figure 2C ). Subsequent analyses focused on ''high-confidence'' factors validated with two or more siRNAs. We focused specifically on aurora kinase A (AURKA) and other mitotic regulators because of their strong functional enrichment and their novelty in the context of splicing regulation.
Physiological function for screen hits was confirmed by analysis of endogenous Bcl-x AS in HeLa cells. siRNAs against 19 factors were tested, and 16 ($85%) significantly shifted Bcl-x splicing toward Bcl-xS ( Figure S3A ). The magnitude of these shifts matched or exceeded fold changes that promote apoptosis in various cell types, indicating physiological significance (Mercatante et al., 2002; Taylor et al., 1999) . As further indication of this significance, AURKA knockdown strongly shifted endogenous Bcl-x protein toward Bcl-xS ( Figure S3B ). This shift was larger than the corresponding mRNA shift, suggesting an amplification effect during translation. Regulation of endogenous Bcl-x by AURKA and other hits also confirmed in MCF7 (breast adenocarcinoma) and PANC1 (pancreatic carcinoma) cells ( Figure S3C ). These lines differ markedly in steady state AURKA levels, with MCF7 (like HeLa) expressing high levels, and PANC1 levels closer to ''normal'' tissue (Ross et al., 2000) . Thus, splicing regulation by AURKA inhibition was not restricted to HeLa cells and occurred irrespective of steady state AURKA levels.
Apoptosis Suppression Defines Direct Regulators of Bcl-x Alternative Splicing
In screening experiments, proapoptotic Bcl-x splicing correlated to apoptosis induction and increased cell death ( Figure S2 ). However, screen hits are likely to include both direct regulators of Bcl-x splicing and factors that influence splicing indirectly via upstream activation of proapoptotic pathways ( Figure 3A ). To define systematically the relationship of screen hits to apoptosis, we retested all 274 validated regulators in Bcl-x reporter cells engineered to overexpress Bcl2. Bcl2 overexpression suppresses mitochondrial permeablization and hence canonical apoptosis progression (Kroemer, 1997) . Importantly, Bcl2 directly antagonizes the function of Bcl-xS, so this strategy also suppresses potential downstream effects of Bcl-xS-Venus produced by the reporter construct. We predicted that Bcl2 overexpression would attenuate the effects of proapoptotic siRNAs that alter Bcl-x splicing as part of a general proapoptotic response, but not siRNAs that target more direct regulators of splicing.
Supporting the latter prediction, depletion of direct regulator SF3B1 increased reporter expression despite Bcl2 overexpression ( Figure 3B ).
Thirty-three percent of 160 high-confidence Bcl-x regulators were totally suppressed by Bcl2 overexpression (Table S3 ). For example, Bcl2 suppressed both cell death and changes in Bcl-x splicing in response to depleting mRNA export factors NXF1 or NUPL2 ( Figure 3C ). By contrast, 67% of factors, including AURKA, showed partial or no suppression of proapoptotic Bcl-x splicing, despite the fact that cell counts showed efficient suppression of cell death. Thus, AURKA, not previously implicated in splicing regulation, functioned independently of Bcl2, whereas mRNA export factors, which directly interact RT-PCR analysis confirmed that SF3B1 knockdown favored short, proapoptotic forms. S/L ratios are quantified to the right of the images; values are the means of three independent measurements ± SD, normalized to controls.
with the spliceosome, were suppressed. Overall, most mRNAsplicing and cell-cycle regulators showed no or partial suppression ( Figure 3D ). Suppressed factors were enriched for functions in transcription, while signaling factors spanned both categories.
Discovery of Mcl1 Alternative Splicing Regulators
To explore functional coordination of apoptotic AS events, we determined all Bcl-x regulators that also control functionally analogous AS of Mcl1. Fifty-two of 160 ''high-confidence'' factors regulated both events, and we validated a subset on endogenous Mcl1 ( Figure 4A , Figure S4 , and Table S4 ). Cellcycle functions were enriched for factors that coregulated Bcl-x and Mcl1, but not factors that regulated only Bcl-x ( Figure 4A ). Similarly, common regulators were disproportionately enriched for splicing functions versus those that only regulated Bcl-x. This result indicates extensive coregulation of Bcl-x and Mcl1 by cell-cycle and splicing factors. In contrast, transcription regulators were enriched only for Bcl-x. Figure 4B schematizes hits in the Bcl-x and Mcl1 screens with known or postulated functions in mRNA metabolism. Hits included ''core'' spliceosome components in Sm ring domains and snRNPs, as well as hnRNP and SR proteins. Interestingly, factors acting late in spliceosome assembly, including U5 snRNP components and factors previously linked to cell-cycle regulation (e.g., CDC40, CDC5L), scored positively for both Bcl-x and Mcl1 (Makarova et al. 2004) .
As an unbiased analysis of Mcl1 AS, we tested siRNA pools for >700 human kinases and phosphatases in the Mcl1 screening assay. Common regulators for Bcl-x and Mcl1 included cell- Tables S1 and  S2 for detailed analysis and validation). (C) GO functional enrichments from primary, revalidated (one or more siRNAs), and high-confidence (two or more siRNAs) hits are shown, plotted by relative statistical significance. See also Figures S1, S2, and S3 and Tables S1  and S2. cycle kinases AURKA, PLK1, and WEE1 ( Figure 4C and Table S5 ). Further, BUB1 scored strongly for Bcl-x and weakly positive for Mcl1, though the latter did not surpass the confidence threshold. Conversely, CDK1 (CDC2) was strongly positive for Mcl1, and weakly so for Bcl-x. These data independently confirm Mcl1 AS regulation by cell-cycle disruption.
Coupling of Cell-Cycle Control and Alternative Splicing
The screen identified many cell-cycle factors, including cancer therapy targets AURKA, PLK1, and survivin (BIRC5). Protein interaction network analysis of screen hits revealed AURKAcentered interactions spanning the cell cycle, spliceosome, and tumor suppressors ( Figure 5A ). As independent validation of this regulation, nocodazole, an inhibitor of microtubule polymerization, and aurora kinase inhibitors ZM447439 and VX-680 strongly induced Bcl-xS formation in a dose-dependent manner ( Figure 5B ). By contrast, the broad-spectrum kinase inhibitor staurosporine induced apoptosis but not Bcl-xS formation, demonstrating specific regulation by cell-cycle inhibitors. ZM447439 and VX-680 inhibit the three mammalian aurora kinases AURKA, AURKB, and germline-restricted AURKC. However, ZM447439 is $20-fold more potent toward AURKB than AURKA in vitro, while VX-680 is $30-fold more potent against AURKA (Ditchfield et al., 2005; Harrington et al., 2004) . Since Bcl-x splicing regulation in screening assays was AURKA specific, VX-680 was used subsequently because of its higher specificity for AURKA. Importantly, nocodazole and VX-680 treatment also shifted endogenous Bcl-x and Mcl1 splicing ( Figure S5 ).
In flow cytometry experiments, aurora inhibitors induced mitotic arrest concomitant with upregulation of the Bcl-x reporter ( Figure 5C ). Bcl-xS-Venus levels in actively cycling G2/M cells were slightly higher than in G1, but the difference was not significant compared to arrested cells ( Figure 5D ). In addition, S phase arrest by double-thymidine block did not affect Bcl-xS-Venus levels, so the splicing response was specific to mitotic arrest ( Figure 5E ). Since transcription and splicing are primarily silenced in M phase (Shin and Manley, 2002) , we considered two possibilities: (1) splicing changes preceded arrest or (2) a subset of cells underwent an abnormal division prior to full arrest, leading to a proapoptotic stress response. To test the latter scenario, cells were synchronized by double-thymidine block, released, and treated with VX-680. Venus fluorescence was measured 16 hr after thymidine release, thus ruling out an intervening mitotic cycle. Figure 5F shows the splicing response to VX-680 in synchronized cells was comparable to asynchronous cells. Apoptosis induction by staurosporine caused no splicing response, regardless of synchronization. These results show that stimuli that activate G2/M and spindle checkpoints trigger proapoptotic Bcl-x splicing, but the response precedes actual arrest.
Downstream Mechanisms of Splicing Regulation
To identify direct splicing regulators downstream of cell-cycle inhibition, we examined expression of splicing factors upon AURKA knockdown, focusing on strong screen hits or factors previously linked to Bcl-x splicing ( Figure S6A ). Among these factors, only ASF/SF2 (SFRS1)-an SR protein previously linked to cell-cycle regulation and a strong hit in the primary screenshowed specific downregulation upon AURKA knockdown ( Figure 6A ) . Inhibition of AURKA with VX-680 also resulted in dose-responsive downregulation of ASF/SF2 ( Figure 6B) . ASF/SF2 mRNA was not significantly reduced upon AURKA inhibition, ruling out transcriptional downregulation or effects on RNA stability ( Figure S6B ). However, VX-680 treatment reduced exogenous green fluorescent protein (GFP)-tagged ASF/SF2 in a manner similar to endogenous ASF/SF2, indicating posttranslational turnover as the main source of ASF/SF2 depletion ( Figure 6C ). AURKA inhibition also induced ASF/SF2 downregulation in apoptosis-resistant cells that overexpress Bcl2 ( Figure S6C ). Therefore, this regulatory pathway functions in cells where apoptosis is suppressed, consistent with our finding that AURKA knockdown shifts Bcl-x splicing when apoptosis is suppressed ( Figure 3C ).
To determine whether Bcl-x is a direct target of ASF/SF2, we used the CLIP method (D) Thirty-three percent of hits were suppressed by Bcl2 overexpression, while 67% showed partial to no suppression. GO functional enrichments within these subsets are shown with p values (see Table S3 ). See also Table S3. APAF1 and TNFSF13 mRNAs were detectable in input but not ASF/SF2 IPs, demonstrating that crosslinking was specific.
Our data show direct regulation of Bcl-x and Mcl1 splicing by ASF/SF2 and downregulation of ASF/SF2 by AURKA inhibition. To test whether ASF/SF2 functions downstream of AURKA inhibition, we examined whether exogenous ASF/SF2 expression could ''rescue'' the splicing response to AURKA inhibition. Bcl-x reporter cells were transfected with mCherry-tagged constructs expressing wild-type (WT) ASF/SF2 or a variant lacking the second RNA recognition motif (DRRM2) domain. After VX-680 treatment, the Bcl-x splicing response in cells expressing ASF/SF2-WT was reduced $50% relative to cells expressing DRRM2 or mCherry alone ( Figure 6F ). CLIP of exogenous GFPtagged ASF/SF2 constructs confirmed deficient recognition of endogenous Bcl-x mRNA by the DRRM2 mutant ( Figure 6G ) (Cá ceres et al., 1997). Therefore, enforced ASF/SF2 expression rescued the effect of AURKA inhibition on Bcl-x splicing, and rescue was dependent on intact splicing regulatory function.
ASF/SF2 regulates apoptosis globally in response to cell-cycle inhibition. Consistent with previous reports, siRNA depletion of ASF/SF2 activates markers of apoptosis (e.g., Annexin-V staining, DNA fragmentation, and caspase cleavage) (data not shown) Karni et al., 2007) . To analyze apoptosis regulation by ASF/SF2 in the context of cell-cycle disruption, we depleted ASF/SF2 by RNAi and analyzed apoptosis markers upon AURKA inhibition with VX-680. ASF/SF2 depletion enhanced caspase activation and Annexin-V staining relative to a nontargeting siRNA control ( Figures 7A and 7B ). In addition, we compared the effects of ASF/SF2 depletion to the depletion of two splicing factors (SRPK1 and SNRP70) that had no significant effect on endogenous Bcl-x splicing and a third factor (Sam68) that has antagonistic effects to ASF/SF2 on Bcl-x splicing ( Figure S3A and Table S1 ) (Paronetto et al., 2007) . ASF/SF2 depletion sensitized cells to VX-680-induced apoptosis relative to SRPK1, SNRP70, or Sam68 depletion. In contrast, ASF/SF2 depletion did not enhance staurosporine-induced apoptosis relative to SRPK1, SNRP70, or Sam68 depletion ( Figure S6D) . We could not reliably analyze the effects of enforced ASF/SF2 expression on apoptotic markers because overexpression was toxic in the time frame required for this analysis. In sum, ASF/SF2 loss-of-function triggers apoptosis and specifically sensitizes cells to apoptosis induced by AURKA inhibition.
To examine broader functions of AS in this apoptotic response, we analyzed caspase-9 (CASP9) and caspase-2 (CASP2) mRNAs, which produce short (S), antiapoptotic, or long (L), proapoptotic isoforms (Schwerk and Schulze-Osthoff, 2005) . Depletion of ASF/SF2 and AURKA favored proapoptotic CASP9 splicing ( Figure 7C ) . In addition, ASF/SF2 depletion favored proapoptotic CASP2 splicing, although AURKA knockdown had no significant effect. We extended our analysis to additional factors with diverse apoptotic functions and AS patterns, including exon skipping, alternative 5 0 ss use, and intron retention. Splice isoforms were measured with an isoform-sensitive qPCR strategy upon A) Bcl-x screen hits were tested for Mcl1 regulation to identify common regulators. High-confidence hits are depicted as a Venn diagram, with GO enrichments listed with p values in the subsets where they were most significantly enriched (see Figure S4 and Table S4 ). (B) Spliceosome-associated proteins (SAPs) that were Bcl-x screen hits are shown with established physical interactions and functional roles. Blue ellipses represent known RNP or protein complexes; pink ellipses contain functionally or structurally related factors. Low-confidence hits are italicized. Factors in gray rectangle have unknown roles in splicing but were identified in proteomic analyses or are similar to known splicing factors (Chen et al., 2007) . Factors are marked as follows: *, high-confidence hit for Mcl1; underlined, phosphorylated in mitosis; +, putative AURKA target; x, putative CDK1 target; and #, putative PLK1 target (Dephoure et al., 2008) . (C) Hits from a kinase/phosphatase screen for Mcl1 splicing regulation are shown, with corresponding Bcl-x regulators. A cutoff of p < 10 À5 in three replicates, or p < 10 À7 in two replicates was applied (see Table S5 ). Cell cycle factors are underlined. See also Figure S4 and Tables S4 and S5. knockdown of various screen hits, revealing widespread changes in splicing upon silencing of cell-cycle regulators ( Figures 7D ). This approach is only semiquantitative, so we focused on identifying biologically robust events by Z score analysis of four independent experiments ( Figures S7A and S7B ). Hierarchical clustering of knockdown profiles revealed overlapping regulation by cell-cycle kinases AURKA, CDC2, and BUB1. In addition, splicing factor profiles grouped by validated spliceosomal interactions; the U2 snRNP factors SF3B1 and SF3A1 overlapped significantly, as did U5 factors PRPF6 and U5-200K. Interestingly, ASF/SF2 targets clustered with AURKA and kinetochore component NDC80, suggesting overlapping regulation in this specific set of mRNAs. As confirmation of direct regulation, binding of ASF/SF2 to selected targets CASP9, CASP2, ATG4, and BMF was established by CLIP ( Figure S7D ).
DISCUSSION

Genome-wide Identification of Alternative Splicing Regulators in Human Cells
We developed a strategy for systematic, high-throughput analysis of AS regulation in human cells. Our siRNA screens identified many spliceosomal regulators of Bcl-x and Mcl1 splicing, as well as functional connections to cell-cycle control, cytoskeleton dynamics, and signal transduction ( Figure 2C ). Strong functional enrichment for known splicing factors was an encouraging indication of specificity. In addition, a high validation rate of screen hits on endogenous AS indicated faithful modeling of physiological regulation in our reporter assays ( Figure S3 ). Broadly, our efforts expand the catalog of factors linking mRNA metabolism and apoptosis and provide a platform for Bcl-x reporter cells were treated with nocodazole, aurora inhibitors VX-680 or ZM447439, or staurosporine for 18 hr. 3-fold dilution series were tested with the following maximum concentrations: 200 nM nocodazole, 10 mM VX-680, 30 mM ZM447439, and 33 nM staurosporine. Percent-Venus-positive values for drug treatments were normalized to DMSO treatments; plotted values reflect means of 8-12 measurements ± SD. Nocodazole, VX-680, and ZM447439, but not staurosporine, caused significant proapoptotic shifts in Bcl-x splicing (p < 0.001). LD 50 ranges derived from cell counts are shown below the x axis. Wells with >33 nM staurosporine had >95% death, so they were not quantified (see Figure S5 ). future high-throughput analyses of mRNA processing in living cells. Screen hits spanned essential processes, such as transcription, cell division, and prosurvival signaling, with extensive mechanistic links to apoptosis, implicating splicing regulation in diverse proapoptotic pathways. The strong correlation of Bcl-xS formation with apoptosis induction and cell death further support a physiological function for splicing regulation in apoptosis ( Figure S2 ). To investigate the functional connection between splicing regulation and apoptosis, we retested factors in cells rendered resistant to apoptosis by exogenous Bcl2 expression (Figure 3) . Surprisingly, cell-cycle factors, like most spliceosomal factors, were generally not affected by Bcl2 expression. Therefore, functional coupling of cell-cycle disruption to proapoptotic splicing remained intact in cells in which the canonical apoptosis pathway was suppressed. This finding suggests that coordinated, proapoptotic splicing could be exploited to target apoptosis-resistant cell populations, such as tumors.
Our screening experiments also revealed functional coordination of proapoptotic splicing events. Fifty-two of 160 ''high-confidence'' Bcl-x regulators affected functionally analogous splicing of Mcl1, and common regulators were disproportionately enriched for splicing and cell-cycle functions ( Figure 4A ). Overlapping spliceosomal regulators of Bcl-x and Mcl1 included ''alternative splicing factors'' (e.g., hnRNPs and SR proteins) and ''core'' spliceosome components spanning most steps in spliceosome assembly ( Figure 4B ). Interestingly, U5 snRNP Figure S6B ). HeLa cells were transfected with a GFP-ASF/SF2 construct, and then treated with VX-680 or DMSO. Western analysis showed that VX-680 downregulated exogenous ASF/SF2, indicating posttranslational turnover. ASF/SF2 downregulation also occurred in apoptosis-resistant cells overexpressing Bcl2 (see Figure S6C ). Bcl-x reporter cells were transfected with mCherry-tagged ASF/SF2, a mutant lacking the second RRM domain (DRRM2), or mCherry alone. Eighteen hours after transfection, cells were treated with 3 mm VX-680 or DMSO for 24 hr. The fraction of Venus-positive cells among mCherry-positive cells was determined by automated microscopy. VX-680-treated samples were background corrected by subtraction of values from DMSO treatment. Values are the means of three separate measurements ± SD, expressed relative to the mCherry-transfected control. ASF/SF2-WT attenuated the Bcl-x response to VX-680 by $50% versus DRRM2. CFP expression was not affected, indicating specific attenuation of Bcl-x splicing. (G) ASF/SF2-DRRM2 shows deficient association with Bcl-x and Mcl1 mRNAs. CLIP analysis of exogenous, GFP-tagged ASF/SF2-WT or -DRRM2 was performed with a-GFP antisera. Values are the means of three independent measurements ± SD. See also Figure S6. and associated factors that function late in spliceosome assembly affected splice-site choice for Bcl-x, Mcl1, and other mRNAs ( Figures 4B, 7C, and 7D) . Current mechanistic models support splice-site pairing early in spliceosome assembly upon U2 snRNP recruitment (Dassah et al., 2009) . Our findings suggest that perturbations of late steps in spliceosome function may promote remodeling of splice-site choice downstream of the rate-limiting steps that normally determine splicing decisions.
Cell-Cycle Disruption Coupled to Proapoptotic Alternative Splicing Our screen for AS regulators identified factors involved in mitotic spindle assembly, kinetochore and centromere dynamics, microtubule transport, centrosome duplication and dynamics, and cell division ( Figure 5A ). Well-characterized pharmacological inhibitors, notably for AURKA, confirmed functional coupling of cell-cycle and splicing regulation ( Figure 5B and Figure S5 ). In flow cytometry experiments, proapoptotic Bcl-x splicing was coupled to mitotic arrest, but not S phase arrest or G2/M in actively cycling cells (Figures 5C-5E ). Since prevailing evidence supports suppression of transcription and splicing in mitosis, it is unlikely that the observed response initiates in mitotically arrested cells (Shin and Manley, 2002) . Moreover, when cells were presynchronized to preclude an intervening cell division, VX-680 still induced a robust splicing response ( Figure 5F ). Therefore, this splicing regulation precedes mitotic arrest, indicating accumulation of prodeath factors in anticipation of G2/M and/or mitotic spindle checkpoints. Since cell-cycle disruption also promoted a proapoptotic switch in CASP9 splicing and altered splicing of other apoptotic regulators, this regulation likely extends to many coregulated mRNAs ( Figures  7C and 7D) .
Many previous studies have linked cell-cycle and splicing regulation, reaching back to the seminal isolation of cell-division cycle (CDC) loci in S. cerevisiae that encode spliceosome components, including factors (CDC5L and CDC40) identified here. Recent genetic and proteomic analyses of mitotic spindle assembly have reasserted the notion that the cell-cycle and splicing machineries are intertwined, but functional consequences have not been established (Bjö rklund et al., 2006 , Rines et al., 2008 . We observe coordinated proapoptotic splicing upon inhibition of key cell-cycle factors, but preceding mitotic arrest, indicating anticipatory upregulation of prodeath factors that may subsequently propagate apoptosis in arrested cells. Since arrested cells cannot mount de novo transcriptional and splicing responses, this finding suggests a genetic mechanism for cell-cycle checkpoint response.
ASF/SF2 Regulates an Apoptotic Splicing Network
We present evidence that ASF/SF2 downregulation mediates a proapoptotic splicing response to cell-cycle disruption. ASF/SF2 was a hit in the Bcl-x and Mcl1 screens, and its overexpression was previously shown to favor Bcl-xL formation (Paronetto et al., 2007) . AURKA inhibition triggered posttranslational turnover of ASF/SF2, but not other SR proteins or splicing factors identified in the screen ( Figures 6A-6C and Figure S6A ). In addition, ASF/SF2 directly binds Bcl-x and Mcl1 mRNAs, and its enforced expression attenuated the effect of AURKA inhibition on Bcl-x splicing ( Figures 6D-6G) .
ASF/SF2 regulation extends beyond Bcl-x to global regulation of apoptosis . ASF/SF2 depletion, but not depletion of several splicing factors that were not validated screen hits, sensitized cells to apoptosis induction by AURKA inhibition ( Figures 7A and 7B ). In contrast, ASF/SF2 depletion did not specifically enhance apoptosis in response to staurosporine ( Figure S6D ). ASF/SF2-mediated splicing regulation extended to other functional targets, including CASP9, which underwent a proapoptotic splicing shift upon depletion of AURKA and ASF/SF2 ( Figure 7C ). Our analysis of some 25 additional AS targets revealed overlapping effects of AURKA and ASF/SF2 inhibition ( Figure 7D ). The fact that some mRNAs (e.g., CASP2) did not respond identically to AURKA and ASF/SF2 knockdown may reflect differential effects of targeting upstream versus direct regulators of splicing, or the activity of additional, unidentified splicing regulators. Nonetheless, these experiments strongly indicate that ASF/SF2 downregulation globally shifts alternative splicing patterns to promote apoptosis upon disruption of the cell cycle.
Alternative Splicing in a Global Context
Our data link coordinated proapoptotic splicing to activated cellcycle checkpoints ( Figure 7E ). These findings are relevant to basic mechanisms of apoptosis in arrested cells, which are poorly defined, and the exploitation of these pathways in cancer therapy. Aberrant expression of AURKA and other prodivision factors promotes spindle checkpoint abrogation, chromosomal instability, and aneuploidy in tumors (Lapenna and Giordano, 2009 ). Our findings indicate that AURKA activation may also propagate oncogenesis by promoting antiapoptotic splicing of crucial cell-death regulators. Conversely, AURKA inhibition elicits parallel upregulation of prodeath variants, which may contribute to its demonstrated efficacy as a cancer drug target. Importantly, this regulation remains intact in apoptosis-resistant cells, suggesting functional and potential therapeutic relevance in tumors.
ASF/SF2 downregulation triggers proapoptotic splicing and promotes apoptosis. Importantly, ASF/SF2 is a proto-oncogene in its own right, and its depletion is linked to genome instability and G2/M arrest (Karni et al., 2007; . Our data highlight RNA targets that may contribute to its transforming properties. Taken together, these findings suggest that ASF/SF2 has multiple, synergistic functions in controlling cell arrest and apoptosis, underscoring its role as a central regulator of mRNA metabolism in cancer. Finally, it bears reiterating that our systematic screening approach was the original source of these biological insights, as well as many new regulators and functional connections not expounded here. We believe future screening efforts will be instrumental in defining global roles for AS in physiological and disease contexts.
EXPERIMENTAL PROCEDURES
siRNA Screening Cells were transfected in triplicate in 384-well plates with >21,000 siRNA SMARTpools (Thermo-Fisher) for known and predicted human genes. Seventy-two hours later, cells were fixed, DAPI stained, and imaged on the Image Xpress Micro microscope (Molecular Devices). Cell counts (DAPI), percent of Venus-positive cells, and average per-cell CFP signal were determined with MetaXpress software. Wells were then assigned probabilistic ''strength'' and ''confidence'' scores in the Venus channel using a support vector machine (SVM) model trained on positive and negative control data ( Figure S1 , Table S1 , and the Extended Experimental Procedures). For independent verification, plate-wide, median-normalized Z scores were also tabulated. Wells with SVM strength scores with false discovery rate (FDR) <10, or z > 2.6 were inspected visually.
Three hundred and sixty-nine positives were retested in a validation screen with four siRNAs from deconvoluted SMARTpools. siRNAs >2 standard deviations (SDs) above negative controls in the Venus channel were deemed positive (Table S2 ). Bcl2-overexpression and Mcl1 screens were performed and analyzed as for the validation screen (Tables S3 and S4) .
RNA Extraction and RT-qPCR
Cellular RNA was extracted with Trizol (Invitrogen) reagent, and 2.5-5 mg were reverse transcribed with Superscript III (Invitrogen) and oligo-dT. Bcl-x, Mcl1, CASP9, and CASP2 isoforms were analyzed by qPCR with primers flanking alternative exon sequences. For each product, a linear range of cDNA input was determined empirically by running of a 2-fold dilution series in 26-28 cycle reactions. Products were run on 5% TBE-PAGE gels, stained with Sybr-Gold (Invitrogen), and quantified with QuantityOne software (Biorad).
Real-time qPCR primer sets were designed with Primer3 webware and tested by electrophoresis to verify correctly sized products (Table S6) . Reactions were prepared with Sybr-Green PCR mix (ABI), run on the ABI 7900HT system, and quantified by a DDC(t) method. Amplicons from alternative regions were first normalized to a constitutive amplicon from the same transcript. To correct for differential primer efficiencies, data were then normalized to negative controls. Z scores were tabulated across four independent experiments and clustered with Eisen Cluster 2.0.
Splicing Assays with Drug Treatments
Sources for inhibitors are in the Extended Experimental Procedures. Cells were treated in 96-well plates for 18-24 hr and analyzed by automated microscopy. For flow cytometry, cells were fixed in 3% PFA/1X PBS then 70% ethanol, permeablized in 1X PBS/0.1% Triton X-100, and stained with 20 mg/ml propidium iodide. DNA content and Venus fluorescence were analyzed on the LSRII system (BD Biosciences).
Western Blotting
Proteins were extracted in RIPA buffer (IX PBS, 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS, protease inhibitors) and quantified by Protein DyeBinding Assay (Biorad). Ten to fifty micrograms of total protein were run on 4%-12% Bis-Tris polyacrylamide gels (Invitrogen), transferred to PVDF membranes, and probed with antibodies listed in Supplemental Data.
CLIP UV crosslinking and RNP purification/visualization were performed as described (Sanford et al., 2009 ). For quantification, CLIP and input samples were treated with Proteinase K (Ambion), and RNA was extracted, reverse transcribed, and analyzed by real-time qPCR.
Apoptosis Assays
Annexin-V-Cy5 (Abcam) staining was quantified by automated microscopy. Caspase activation was measured with the DEVD-Nucview 488 reagent (Biotum), which stains nuclei specifically after it is cleaved by caspase-3. Cells were incubated for 1 hr with 2.5 mM substrate, fixed, and analyzed by automated microscopy.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, seven figures, and six tables and can be found with this article online at doi:10.1016/ j.cell.2010.07.019.
